Beloranib is being studied as a first-in-class obesity therapy that demonstrates a unique mechanism of action through methionine aminopeptidase 2 (MetAP2 ) inhibition. MetAP2 inhibitors work by re-establishing balance to the ways the body packages and metabolizes fat. Inhibitors of MetAP2 reduce the production of new fatty acid molecules by the liver and help to convert stored fats into useful energy.
Through targeting this key enzyme, beloranib restores balance to the production and utilization of fat, resulting in positive metabolic cascades. Due to its unique mechanism, beloranib may have the potential to be prescribed in combination with other treatments, making it complementary to, rather than competitive with, current therapies.
We are encouraged by results from early clinical trials with beloranib and have completed two Phase 2a clinical trials to evaluate safety, efficacy and pharmacokinetics (absorption and disposition of beloranib in the blood stream) in more patients studied over a longer period of time. Three consecutive Phase 1b studies with beloranib demonstrated rapid weight loss averaging approximately one kilogram (2.2 pounds) per week, with reductions in body fat, improvements in cardiovascular risk factors and tolerability that was encouraging.
Zafgen holds exclusive worldwide rights (exclusive of Korea) for development and commercialization of beloranib. The company licensed beloranib from CKD Pharma.